Clinical outcomes in kidney transplant recipients receiving tixagevimab/cilgavimab for outpatient treatment of COVID-19: a single-center retrospective study

Clinical outcomes in kidney transplant recipients receiving tixagevimab/cilgavimab for outpatient treatment of COVID-19: a single-center retrospective study

Kidney transplant recipients (KTR) show higher morbidity and mortality from COVID-19 than the general population and have an impaired response to vaccination. Outpatient treatment with tixagevimab/cilgavimab prevented clinical deterioration in unvaccinated patients with COVID-19 during periods of Al...

Full description

Saved in:
Bibliographic Details
Main Authors: Bilgin Osmanodja, Friederike Bachmann, Mira Choi, Wiebke Duettmann, Georgios Eleftheriadis, Fabian Halleck, Marcel G. Naik, Eva Schrezenmeier, Bianca Zukunft, Klemens Budde
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Transplantation
Subjects:
COVID-19
COVID-19 drug treatment
kidney transplantation
immunocompromised host
observational study
Online Access:https://www.frontiersin.org/articles/10.3389/frtra.2025.1579226/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items